According to experts at the IAS 2025 meeting in Kigali, Rwanda, AI revolutionizes HIV vaccine development by enhancing design ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV infection.

Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating patient-focused innovations for HIV prevention and treatment.

WHO’s director general described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the absence of a vaccine.

The FDA has accepted MSD’s doravirine/islatravir new drug application (NDA) for review to treat adults with virologically suppressed HIV-1.

A GNA feature by Laudia Sawer Tema, July 12, GNA - On any ordinary morning, Maame Esi, an HIV mentor mother, stands among other mothers at the antenatal clinic of the Tema General Hospital, scanning ...

Cuts to U.S. foreign aid will endanger HIV treatment and prevention services globally and are likely to reverse decades of ...

In an interview with The News & Observer, Dr. Barton Haynes talks future of HIV vaccine development after HHS canceled the ...

But in the last six months, the sudden withdrawal of U.S. money has caused a “systemic shock,” U.N. officials warned, adding ...